AGTCinactive

APPLIED GENETIC TECHNOLOGIES CORP

Healthcare·Ophthalmology·Commercial

Ophthalmology

APPLIED GENETIC TECHNOLOGIES CORP (AGTC): 10 pipeline candidates · ~7 mo cash runway. Updated within the last hour.

7.1/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.8

6.6 months

Financial Health6.6

D/E 2.25 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

10 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for APPLIED GENETIC TECHNOLOGIES CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$34.2M

Quarterly Burn

$16.0M

Runway

6.6 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jan 2027

Today~7 mo out

Catalyst within runway

Pipeline (10 candidates)

Drug	Phase	Indication
achma3	Phase 1/Phase 2	Achromatopsia (ACHM) caused by mutations in the CNGA3 gene
achmb3	Phase 1/Phase 2	Achromatopsia (ACHM) caused by mutations in the CNGB3 gene
agtc 401	Preclinical	Achromatopsia B3 (ACHMB3)
agtc-501	Phase 2	X-linked retinitis pigmentosa (XLRP)
applied laboratories sterile saline	Approved	Ophthalmic
dry amd gene therapy	Preclinical	Dry age-related macular degeneration (AMD)
gjb2 gene therapy	Preclinical	Sensorineural hearing loss caused by a mutation in GJB2
optogenetic product candidate	Phase 1/Phase 2	Advanced retinal disease
tri pol 43 contact lens	Approved	Ophthalmic
xlrp product candidate	Phase 2/Phase 3	X-linked retinitis pigmentosa (XLRP)

·CEO: Susan B. Washer

Frequently asked questions

How many drug candidates are in APPLIED GENETIC TECHNOLOGIES CORP's pipeline?

APPLIED GENETIC TECHNOLOGIES CORP (AGTC) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is APPLIED GENETIC TECHNOLOGIES CORP's lead drug candidate?

APPLIED GENETIC TECHNOLOGIES CORP's most advanced tracked candidate is achma3 (Phase 1/Phase 2) for Achromatopsia (ACHM) caused by mutations in the CNGA3 gene.

What is APPLIED GENETIC TECHNOLOGIES CORP's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, APPLIED GENETIC TECHNOLOGIES CORP has approximately 6.6 months of cash runway.

Who is the CEO of APPLIED GENETIC TECHNOLOGIES CORP?

Susan B. Washer is the chief executive officer of APPLIED GENETIC TECHNOLOGIES CORP (AGTC).

Get the full picture on APPLIED GENETIC TECHNOLOGIES CORP

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free Analysis Browse Calendar